Opioid antagonists with minimal sedation for opioid withdrawal

Scolaris Content Display Scolaris Content Display

Ir a:

Figure 1

Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.

Figure 2

Methodological quality summary: review authors' judgements about each methodological quality item for each included study.

Figure 3

Forest plot of comparison: 1 Antagonist‐adrenergic combination versus adrenergic agonist, outcome: 1.1 Peak withdrawal severity.

Figure 4

Forest plot of comparison: 1 Antagonist‐adrenergic combination versus adrenergic agonist, outcome: 1.2 Overall withdrawal severity.

Figure 5

Forest plot of comparison: 1 Antagonist‐adrenergic combination versus adrenergic agonist, outcome: 1.3 Completion rate.

Analysis 1.1

Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 1 Peak withdrawal severity.

Analysis 1.2

Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 2 Overall withdrawal severity.

Analysis 1.3

Comparison 1 Antagonist‐adrenergic combination versus adrenergic agonist, Outcome 3 Completion rate.

Comparison 1. Antagonist‐adrenergic combination versus adrenergic agonist

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Peak withdrawal severity Show forest plot	2		Std. Mean Difference (IV, Random, 95% CI)	Totals not selected

1.1 Naltrexone	2		Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
1.2 Naloxone	1		Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2 Overall withdrawal severity Show forest plot	4		Std. Mean Difference (IV, Random, 95% CI)	Totals not selected

2.1 Naltrexone	3		Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 Naloxone	1		Std. Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
3 Completion rate Show forest plot	8		Risk Ratio (M‐H, Random, 95% CI)	Totals not selected

3.1 Naltrexone	4		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
3.2 Naloxone	5		Risk Ratio (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]

Comparison 1. Antagonist‐adrenergic combination versus adrenergic agonist